NCT00180115View on ClinicalTrials.gov

AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 29, 1996

Study Completion Date

November 30, 2008

Conditions
Leukemia, Nonlymphoblastic, Acute
Interventions
DRUG

Cytarabine Dosage

Trial Locations (1)

01307

Medical Department I, University Hospital Carl Gustav Carus, Dresden

All Listed Sponsors
lead

Technische Universität Dresden

OTHER

NCT00180115 - AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients | Biotech Hunter | Biotech Hunter